Taipei Exchange - Delayed Quote TWD

Mycenax Biotech Inc. (4726.TWO)

32.80
+0.90
+(2.82%)
As of 12:19:15 PM GMT+8. Market Open.
Loading Chart for 4726.TWO
  • Previous Close 31.90
  • Open 32.35
  • Bid 32.75 x --
  • Ask 32.85 x --
  • Day's Range 32.10 - 32.80
  • 52 Week Range 27.40 - 65.20
  • Volume 48,000
  • Avg. Volume 278,304
  • Market Cap (intraday) 6.803B
  • Beta (5Y Monthly) 0.76
  • PE Ratio (TTM) --
  • EPS (TTM) -2.27
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Mycenax Biotech Inc., a contract development and manufacturing organization company, provides biopharmaceutical services and solutions for drug development and production in Taiwan, Japan, Korea, Singapore, rest of the Asia-Pacific regions, Europe, and the United States. The company's services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers plasmid DNA, antibody-drug conjugates, cell and gene therapy, and exosomes products and services. The company was founded in 2001 and is headquartered in Zhubei, Taiwan.

www.mycenax.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 4726.TWO

View More

Performance Overview: 4726.TWO

Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

4726.TWO
24.42%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
8.42%

1-Year Return

4726.TWO
26.29%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
1.87%

3-Year Return

4726.TWO
5.07%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
35.08%

5-Year Return

4726.TWO
62.78%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
93.90%

Compare To: 4726.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4726.TWO

View More

Valuation Measures

Annual
As of 5/8/2025
  • Market Cap

    6.68B

  • Enterprise Value

    7.28B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    9.70

  • Price/Book (mrq)

    3.30

  • Enterprise Value/Revenue

    10.65

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -68.30%

  • Return on Assets (ttm)

    -8.08%

  • Return on Equity (ttm)

    -20.90%

  • Revenue (ttm)

    683.92M

  • Net Income Avi to Common (ttm)

    -467.12M

  • Diluted EPS (ttm)

    -2.27

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    276.86M

  • Total Debt/Equity (mrq)

    43.66%

  • Levered Free Cash Flow (ttm)

    -489.76M

Research Analysis: 4726.TWO

View More

Company Insights: 4726.TWO

Research Reports: 4726.TWO

View More

People Also Watch